EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells

Reha Sertac Ilhan iD, Merve Gurboga iD, Turgut Sekerler, Pinar Ulupinar, Derya Ozsavci, Ozlem Bingol Ozakpinar iD

International Journal of Molecular Sciences · 28.07.2026 · 27 (15) · 6759

DOI: 10.3390/ijms27156759 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.07.2026. Verfasst von Reha Sertac Ilhan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye. Hauptthemen laut MEDLINE: Triterpenes, Colorectal Neoplasms, Down-Regulation, Receptor Protein-Tyrosine Kinases. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific and Technological Research Council of Türkiye.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a major cause of cancer mortality worldwide, highlighting the need for novel molecular targets and alternative therapeutic strategies. TYRO3, a member of the TAM receptor tyrosine kinase family, has been associated with tumor progression and poor prognosis in CRC. In this study, the effects of the natural compounds Meleagrin and Cucurbitacin B on TYRO3 expression and CRC cell behavior were investigated in HCT-116 and HT-29 cells. Cell proliferation, apoptosis, migration, and TYRO3 expression were evaluated using functional and expression-based analyses. Both compounds modulated TYRO3 expression and suppressed proliferation and wound closure dynamics in CRC cells. Cucurbitacin B exerted more pronounced antiproliferative and pro-apoptotic effects, whereas Meleagrin demonstrated antiproliferative activity with comparatively lower effects on normal colon epithelial cells (CCD 841 CoN), suggesting a potentially more favorable selectivity profile. Collectively, these findings support further mechanistic investigation of TYRO3-modulating natural compounds as potential therapeutic candidates for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriterpenesColorectal NeoplasmsDown-RegulationReceptor Protein-Tyrosine KinasesGene Expression Regulation, NeoplasticAntineoplastic AgentsHumansCell ProliferationApoptosisCell MovementHT29 CellsHCT116 CellsCell Line, Tumor

Stichwörter der Autor:innen

Cucurbitacin BTYRO3apoptosiscolorectal cancermeleagrinreceptor expression

Substanzen

Triterpenescucurbitacin BTYRO3 protein, humanReceptor Protein-Tyrosine KinasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biochemistry, Faculty of Pharmacy, Marmara University, Istanbul 34854, Türkiye.

ORCID-Profile: Reha Sertac Ilhan, Merve Gurboga, Ozlem Bingol Ozakpinar

Förderung

  • The Scientific and Technological Research Council of Türkiye

Zitieren

APA

Ilhan, R. S., Gurboga, M., Sekerler, T., Ulupinar, P., Ozsavci, D., & Bingol Ozakpinar, O. (2026). Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells. International Journal of Molecular Sciences, 27(15), 6759. https://doi.org/10.3390/ijms27156759

Vancouver

Ilhan RS, Gurboga M, Sekerler T, Ulupinar P, Ozsavci D, Bingol Ozakpinar O. Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells. International Journal of Molecular Sciences. 2026;27(15):6759. doi:10.3390/ijms27156759

BibTeX
@article{Ilhan2026,
  author = {Ilhan, Reha Sertac and Gurboga, Merve and Sekerler, Turgut and Ulupinar, Pinar and Ozsavci, Derya and Bingol Ozakpinar, Ozlem},
  title = {Anticancer Effects of Cucurbitacin B and Meleagrin Associated with TYRO3 Downregulation in Colorectal Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6759},
  doi = {10.3390/ijms27156759}
}
Kostenlos starten →